Synergetics Usa Inactive 10-Q9 Dec 132014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Oct. 31, 2013	Dec. 06, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'SYNERGETICS USA INC	'
Entity Central Index Key	'0000836429	'
Current Fiscal Year End Date	'--07-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	25,296,106
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Oct-13	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Oct. 31, 2013	Jul. 31, 2013
In Thousands, unless otherwise specified	Oct. 31, 2013	Jul. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$13,537	$12,470
Accounts receivable, net of allowance for doubtful accounts of $555 and $495, respectively	12,730	14,425
Inventories	16,029	14,825
Income taxes refundable	0	254
Prepaid expenses	1,381	996
Deferred income taxes	1,887	1,827
Total current assets	45,564	44,797
Property and equipment, net	8,998	8,962
Intangible and other assets	'	'
Goodwill	12,228	12,155
Other intangible assets, net	11,603	11,715
Deferred income taxes	3,405	3,557
Patents, net	1,440	1,411
Cash value of life insurance	96	96
Total assets	83,334	82,693
Current Liabilities	'	'
Accounts payable	3,109	3,237
Accrued expenses	3,203	3,486
Income taxes payable	81	0
Deferred revenue	1,288	1,288
Total current liabilities	7,681	8,011
Long-Term Liabilities	'	'
Deferred revenue	14,208	14,530
Total long-term liabilities	14,208	14,530
Total liabilities	21,889	22,541
Commitments and contingencies (Note 8)	'	'
Stockholders' Equity	'	'
Common stock at October 31, 2013 and July 31, 2013, $0.001 par value, 50,000,000 shares authorized; 25,296,106 and 25,292,960 shares issued and outstanding, respectively	25	25
Additional paid-in capital	27,673	27,489
Retained earnings	34,031	33,097
Accumulated other comprehensive loss:	'	'
Foreign currency translation adjustment	-284	-459
Total stockholders' equity	61,445	60,152
Total liabilities and stockholders' equity	$83,334	$82,693

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Oct. 31, 2013	Jul. 31, 2013
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Jul. 31, 2013
Current Assets	'	'
Accounts receivable, allowance for doubtful accounts	$555	$495
Stockholders' Equity	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	25,296,106	25,292,960
Common stock, shares outstanding (in shares)	25,296,106	25,292,960

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012
Condensed Consolidated Statements of Income and Comprehensive Income [Abstract]	'	'
Net sales	$15,530	$14,620
Cost of sales	6,606	6,147
Gross profit	8,924	8,473
Operating expenses	'	'
Research and development	1,197	861
Sales and marketing	3,576	3,263
Medical device excise tax	125	0
General and administrative	2,635	2,408
Total operating expenses	7,533	6,532
Operating income	1,391	1,941
Other income (expenses)	'	'
Investment income	4	7
Miscellaneous	0	-3
Total other income (expenses)	4	4
Income from operations before provision for income taxes	1,395	1,945
Provision for income taxes	460	593
Net income	935	1,352
Earnings per share:	'	'
Basic earnings per share (in dollars per share)	$0.04	$0.05
Diluted earnings per share (in dollars per share)	$0.04	$0.05
Basic weighted average common shares outstanding (in shares)	25,294,020	25,160,757
Diluted weighted average common shares outstanding (in shares)	25,380,940	25,286,184
Net income	935	1,352
Foreign currency translation adjustment	175	70
Comprehensive income	$1,110	$1,422

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012
Cash Flows from Operating Activities	'	'
Net income	$935	$1,352
Adjustments to reconcile net income to net cash used in operating activities	'	'
Depreciation	266	305
Amortization	180	161
Provision for doubtful accounts receivable	56	-3
Stock-based compensation	185	243
Deferred income taxes	92	97
(Increase) decrease in:	'	'
Accounts receivable	1,629	-169
Inventories	-1,152	-1,577
Prepaid expenses	-236	-229
(Decrease) increase in:	'	'
Accounts payable	-135	31
Accrued expenses	-267	-42
Deferred revenue	-322	-322
Income taxes payable	300	50
Net cash provided by (used in) operating activities	1,530	-103
Cash Flows from Investing Activities	'	'
Purchase of property and equipment	-302	-106
Acquisition of patents and other intangibles	-82	-78
Net cash used in investing activities	-384	-184
Foreign exchange rate effect on cash and cash equivalents	-79	-69
Net decrease in cash and cash equivalents	1,067	-356
Cash and cash equivalents	'	'
Beginning	12,470	12,680
Ending	$13,537	$12,324

General

General	3 Months Ended
General	Oct. 31, 2013
General [Abstract]	'
General	'
	Note 1. General

	Nature of business: Synergetics USA, Inc. (“Synergetics USA” or the “Company”) is a Delaware corporation incorporated on June 2, 2005, in connection with the reverse merger of Synergetics, Inc. (“Synergetics”) and Valley Forge Scientific Corp. (“Valley Forge”) and the subsequent reincorporation of Valley Forge (the predecessor to Synergetics USA) in Delaware. Synergetics USA is a medical device company. Through continuous improvement and development of its people, the Company’s mission is to design, manufacture and market innovative surgical devices, surgical equipment and consumables of the highest quality in order to assist and enable surgeons who perform surgery around the world to provide a better quality of life for their patients. The Company’s primary focus is on the surgical disciplines of ophthalmology and neurosurgery. Its distribution channels include a combination of direct and independent vitreoretinal sales organizations and important strategic alliances with market leaders. The Company's product lines focus upon precision engineered, disposable and reusable devices, surgical equipment, procedural kits and the delivery of various energy modalities for the performance of surgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency energy for electrosurgery and lesion generation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. The Company is located in O’Fallon, Missouri, King of Prussia, Pennsylvania and Corby, United Kingdom. During the ordinary course of its business, the Company grants unsecured credit to its domestic and international customers.

	Basis of presentation: The unaudited condensed consolidated financial statements include the accounts of Synergetics USA and its wholly owned subsidiaries: Synergetics, Synergetics Development Company, LLC, Synergetics Delaware, Inc. and Synergetics IP, Inc. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair presentation have been included. Operating results for the three months ended October 31, 2013, are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2014. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended July 31, 2013, and notes thereto included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on October 1, 2013 (the “Annual Report”).

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Oct. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 2. Summary of Significant Accounting Policies

	The Company’s significant accounting policies are disclosed in the Annual Report. In the first three months of fiscal 2014, no significant accounting policies were changed.

Acquisition_of_MISS_Ophthalmic

Acquisition of MISS Ophthalmics LTD	3 Months Ended
Acquisition of MISS Ophthalmics LTD	Oct. 31, 2013
Acquisition of MISS Ophthalmics LTD [Abstract]	'
Acquisition of MISS Ophthalmics LTD	'
	Note 3. Acquisition of M.I.S.S. Ophthalmics, LTD

	On July 8, 2013, the Company acquired M.I.S.S. Ophthalmics Limited (“M.I.S.S.”), a private ophthalmology distribution company incorporated in England and Wales, for net cash consideration of $2.8 million. M.I.S.S. was the Company’s distributor of ophthalmic products in the United Kingdom, and its wholesale distribution activities contributed approximately $1.1 million in revenue to the Company in fiscal 2013. M.I.S.S. generated total revenue of approximately $3.2 million during its fiscal year ended March 31, 2013.

	The Company has allocated the purchase price to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair value at the date of acquisition resulting in the recognition of $0.9 million of intellectual property and $1.5 million of goodwill.

	No supplemental pro-forma information is presented for the acquisition due to the immaterial effect of the acquisition on the Company's financial statements.

OEM_Partner_Agreements

OEM Partner Agreements	3 Months Ended
	Oct. 31, 2013
OEM Partner Agreements [Abstract]	'
OEM Partner Agreements	'
	Note 4. OEM Partner Agreements

	The Company sells all of its generators and a majority of its neurosurgery instruments and accessories to two U.S.-based national and international original equipment manufacturer ("OEM") partners as described below:

	Codman

	In the neurosurgical market, the bipolar electrosurgical system manufactured by Valley Forge prior to the merger has been sold for over 30 years through a series of distribution agreements with Codman, an affiliate of Johnson & Johnson. On April 2, 2009, the Company executed a three-year distribution agreement with Codman for the continued distribution by Codman of certain bipolar generators and related disposables and accessories, effective January 1, 2009. In addition, the Company entered into a new, three-year license agreement, which provides for the continued licensing of the Company’s Malis^® trademark to Codman for use with certain Codman products, including those covered by the distribution agreement.

	On November 16, 2009, the Company announced the signing of an addendum to its agreement with Codman. Under the terms of the revised agreement, Codman has the exclusive right to market and distribute the Company’s Malis^® branded disposable bipolar forceps produced by Synergetics. Codman began distribution of the disposable bipolar forceps on December 1, 2009, domestically, and on February 1, 2010, internationally.

	Both agreements expired on December 31, 2011 and have renewed for three years. In December 2010, Codman elected to exercise its option of exclusive distribution with respect to the bipolar generators and related disposables and accessories.

	Total sales to Codman and its respective percent of the Company’s net sales in the three months ended October 31, 2013 and 2012, including the historical sales of generators, accessories and disposable cord tubing that the Company has supplied in the past, as well as the disposable bipolar forceps sales resulting from the addendum to the existing distribution agreement, were as follows:

		Three Months Ended			Three Months Ended
		31-Oct-13			31-Oct-12
	Net Sales	$	4,101		$	2,816
	Percent of net sales		26.4	%		19.3	%

	Stryker Corporation (“Stryker”)

	The Company supplies a multi-channel ablation generator, used for minimally invasive pain treatment, to Stryker pursuant to a supply and distribution agreement dated as of October 25, 2004, as amended. The agreement expires on June 30, 2015.

	On March 31, 2010, the Company entered into a supply agreement with Stryker pursuant to which the Company agreed to supply Stryker with disposable ultrasonic aspirator instrument tips and certain other consumable products used in conjunction with Stryker’s ultrasonic aspirator console and handpieces. The agreement expires on March 31, 2016.

	Total sales to Stryker and its respective percent of the Company’s net sales in the three months ended October 31, 2013, and 2012, including the historical sales of pain control generators, and accessories that the Company has supplied in the past, as well as the disposable ultrasonic instrument tips sales and certain other consumable products resulting from the new agreements, were as follows:

		Three Months Ended			Three Months Ended
		31-Oct-13			31-Oct-12
	Net Sales	$	2,162		$	2,559
	Percent of net sales		13.9	%		17.5	%

	No other customer comprises more than 10 percent of sales in any given quarter.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Oct. 31, 2013
Stock-Based Compensation [Abstract]	'
Stock-Based Compensation	'
	Note 5. Stock-Based Compensation

	Stock Option Plans

	The following table provides information about stock-based awards outstanding at October 31, 2013:

			Shares			Weighted Average		Weighted Average
			Shares			Exercise Price		Fair Value
	Options outstanding beginning of period			747,662		$	4.17	$	3.23
	For the period August 1, 2013 through October 31, 2013
	Granted			--			--		--
	Forfeited			--			--		--
	Exercised			--			--		--
	Options outstanding, end of period			747,662		$	4.17	$	3.23
	Options exercisable, end of period			545,883		$	3.79	$	2.95

	There were no options granted in the first quarter of fiscal 2014. Each independent director receives an option to purchase 10,000 shares of the Company’s Common Stock each year in which he or she is elected, appointed, or continues to serve as a director pursuant to the Amended and Restated 2005 Non-Employee Directors’ Stock Option Plan. These options vest pro-ratably on a quarterly basis over the next year of service on the Board. During the second quarter of fiscal 2013, there were options to purchase 60,000 shares of Common Stock granted to the Company’s independent directors, which vest pro-ratably on a quarterly basis over the next year of service. These options also vest upon a change of control event. The Company recorded $43,000 and $68,000 of compensation expense for the three months ended October 31, 2013 and 2012, respectively, with respect to the directors’ options.

	During the second quarter of fiscal 2013, there were options to purchase 82,227 shares of Common Stock granted to the officers and employees of the Company. These options were granted in conjunction with the Company’s annual review of compensation as of August 1, 2012 and vest on a quarterly basis over the next four years of service. The Company recorded $17,000 of compensation expense for the three months ended October 31, 2013, related to these options. In addition, the Company recorded $48,000 and $48,000 of compensation expense for the three months ended October 31, 2013 and 2012, respectively, for previously granted options.

	The Company expects to issue new shares as options are exercised. As of October 31, 2013, the future compensation cost expected to be recognized for currently outstanding stock options is approximately $225,000 for the remainder of fiscal 2014, $254,000 in fiscal 2015, $226,000 in fiscal 2016 and $88,000 in fiscal 2017.

	The fair value of all options granted during the second quarter of fiscal 2013 was determined at the date of the grant using the Black-Scholes option-pricing model and the following assumptions:

	Expected average risk-free interest rate	1.72%
	Expected average life (in years)	10
	Expected volatility	70.50%
	Expected dividend yield	0.00%

	The expected average risk-free rate is based on the 10-year U.S. treasury yield curve in December of 2012. The expected average life represents the period of time that the options granted are expected to be outstanding giving consideration to the vesting schedules, historical exercises and forfeiture patterns. Expected volatility is based on historical volatilities of the Company’s Common Stock. The expected dividend yield is based on historical information and the Board of Directors' plan, to reinvest available resources in the growth of the Company for the foreseeable future.
	The intrinsic value of the in-the-money stock options outstanding was $393,000 and $2.0 million at October 31, 2013 and 2012, respectively. The intrinsic value of in-the-money exercisable stock options was $375,000 and $1.2 million at October 31, 2013 and 2012, respectively.

	Restricted Stock Plans

	Under the Amended and Restated Synergetics USA, Inc. Stock Plan (the "2001 Plan"), the Company’s common stock may be granted at no cost to certain employees and consultants of the Company. Certain plan participants are entitled to cash dividends and voting rights for their respective shares. Restrictions limit the sale or transfer of these shares during a vesting period whereby the restrictions lapse either pro-ratably over a three-year or five-year vesting period or at the end of the third or fifth year. These shares also vest upon a change of control event. Upon issuance of stock under the 2001 Plan, unearned compensation equivalent to the market value at the date of the grant is charged to stockholders’ equity and subsequently amortized to expense over the applicable restriction period. As of October 31, 2013, there was approximately $928,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Company’s 2001 Plan. The cost is expected to be recognized over a weighted average period of four years which is generally the vesting period. The following table provides information about restricted stock grants during the three-month period ended October 31, 2013:

			Number of Shares			Weighted Average Grant
			Number of Shares			Date Fair Value
	Balance as of July 31, 2013			405,248		$	3.79
	Granted			--			--
	Forfeited			(2,001	)	$	3.47
	Vested			(51,117	)	$	2.97
	Balance as of October 31, 2013			352,130		$	3.91

Fair_Value_Information

Fair Value Information	3 Months Ended
Fair Value Information	Oct. 31, 2013
Fair Value Information [Abstract]	'
Fair Value Information	'
	Note 6. Fair Value Information

	Fair value is an exit price that represents the amount that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants.

	The Company does not have any financial assets which are required to be measured at fair value on a recurring basis. Non-financial assets such as goodwill, intangible assets and property, plant and equipment are measured at fair value when there is an indicator of impairment or at least annually and recorded at fair value only when impairment is recognized. No impairment indicators existed as of October 31, 2013.

	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short maturity of these items.

Supplemental_Balance_Sheet_Inf

Supplemental Balance Sheet Information	3 Months Ended
Supplemental Balance Sheet Information	Oct. 31, 2013
Supplemental Balance Sheet Information [Abstract]	'
Supplemental Balance Sheet Information	'
	Note 7. Supplemental Balance Sheet Information

	Inventories: Inventories as of October 31, 2013 and July 31, 2013, respectively, were as follows (dollars in thousands):

		October 31,2013		31-Jul-13
	Raw material and component parts	$	6,786	$	7,418
	Work in progress		1,829		1,133
	Finished goods		7,414		6,274
		$	16,029	$	14,825

	Property and Equipment: Property and equipment as of October 31, 2013 and July 31, 2013, respectively, were as follows:

		31-Oct-13		31-Jul-13
	Land	$	730	$	730
	Building and improvements		6,515		6,365
	Machinery and equipment		8,799		8,665
	Furniture and fixtures		1,040		1,058
	Software		1,108		1,107
	Construction in progress		275		177
			18,467		18,102
	Less accumulated depreciation		9,469		9,140
		$	8,998	$	8,962

	Other Intangible Assets: Information regarding the Company’s other intangible assets as of October 31, 2013 and July 31, 2013, respectively, were as follows:

		Gross Carrying		Accumulated		Net
		Value		Amortization		Net
		31-Oct-13
	Proprietary know-how	$	4,057	$	2,348	$	1,709
	Trademark		5,940		--		5,940
	Licensing agreement		5,834		2,834		3,000
	Customer relationships		557		17		540
	Other intangibles		427		13		414
	Patents		2,350		910		1,440
		$	19,165	$	6,122	$	13,043

		31-Jul-13
	Proprietary know-how	$	4,057	$	2,286	$	1,771
	Trademark		5,938		--		5,938
	Licensing agreement		5,834		2,766		3,068
	Customer relationships		531		--		531
	Other intangibles		407		--		407
	Patents		2,270		859		1,411
		$	19,037	$	5,911	$	13,126

	Goodwill of $1,568,000 and other intangibles of $984,000 are a result of the acquisition of M.I.S.S. completed on July 8, 2013. Goodwill of $10,660,000 and proprietary know-how of $4,057,000 are a result of the reverse merger transaction completed on September 21, 2005.

	The Company did not incur costs to renew or extend the term of acquired intangible assets during the period ended October 31, 2013. Amortization expense is included in general and administrative expense and was $180,000 for the three months ended October 31, 2013. Amortization expense for the next five years is expected to approximate $800,000 annually.

	Pledged Assets; Short and Long-Term Debt (Excluding Revenue Bonds Payable): Short-term debt as of October 31, 2013 and July 31, 2013, consisted of the following:

	Revolving Credit Facility: The Company has a credit facility with a bank which allows for borrowings of up to $9.5 million (collateral available on October 31, 2013 permits borrowings up to $8.9 million) with an interest rate based on either the one-, two- or three-month LIBOR plus 2.0 percent and adjusting each quarter based upon our leverage ratio. As of October 31, 2013, interest under the facility would have been 2.24 percent. The unused portion of the facility is charged at a rate of 0.20 percent. There were no borrowings under this facility at October 31, 2013. Outstanding amounts are collateralized by the Company’s domestic receivables and inventory. This credit facility was amended on September 30, 2013, to extend the termination date through September 30, 2016.
	The facility has two financial covenants: a maximum leverage ratio of 3.75 times and a minimum fixed charge coverage ratio of 1.1 times. As of October 31, 2013, the leverage ratio was 0.61 times and the minimum fixed charge coverage ratio was 553.1 times. The facility restricts the payment of dividends if, following the distribution, the fixed charge coverage ratio would fall below the required minimum.

	Equipment Line of Credit: Under this credit facility, the Company may borrow up to $1.0 million, with interest at one-month LIBOR plus 3.0 percent. Pursuant to the terms of the equipment line of credit, under no circumstances shall the rate be less than 3.5 percent per annum. The unused portion of the facility is not charged a fee. There were no borrowings under this facility at October 31, 2013. The equipment line of credit was amended on September 30, 2013, to extend the maturity date to September 30, 2016.

	Deferred Revenue: Deferred revenue as of October 31, 2013 and July 31, 2013, respectively, consisted of the following:

		31-Oct-13		31-Jul-13
	Deferred revenue – Alcon settlement	$	15,496	$	15,818
	Less: Short-term portion		1,288		1,288
	Long-term portion	$	14,208	$	14,530

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Oct. 31, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	Note 8. Commitments and Contingencies

	The Company has entered into change of control agreements with each of its President and Chief Executive Officer, Chief Financial Officer, Chief Scientific Officer, Vice President of Domestic Sales and Vice President of Marketing and Technology. The change of control agreements with its executive officers provide that if employment is terminated within one year for cause or disability following a change in control (as each term is defined in the change in control agreements), as a result of the officers’ death, or by the officer other than as an involuntary termination (as defined in the change in control agreements), the Company shall pay the officer all compensation earned or accrued through his or her employment termination date, including (i) base salary; (ii) reimbursement for reasonable and necessary expenses; (iii) vacation pay; (iv) bonuses and incentive compensation; and (v) all other amounts to which they are entitled under any compensation or benefit plan of the Company (“Standard Compensation Due”).

	If the officer’s employment is terminated within one year following a change of control without cause and for any reason other than death or disability, including an involuntary termination, and provided the officer enters into a separation agreement within 30 days of his or her employment termination, he or she shall receive the following: (i) all Standard Compensation Due and any amount payable as of the termination date under the Company’s objectives-based incentive plan, the sum of which shall be paid in a lump sum immediately upon such termination; and (ii) an amount equal to one times his or her annual base salary at the rate in effect immediately prior to the change in control, to be paid in 12 equal monthly installments beginning in the month following his or her employment termination. Furthermore, all of the officer’s awards of shares or options shall immediately vest and be exercisable for one year after the date of his or her employment termination.

	Various claims, incidental to the ordinary course of business, are pending against the Company. In the opinion of management, after consultation with legal counsel, resolution of these matters is not expected to have a material effect on the accompanying financial statements.

	The Company is subject to regulatory requirements throughout the world. In the normal course of business, regulatory agencies may require companies in the medical industry to change their products or operating procedures, which could affect the Company. The Company regularly incurs expenses to comply with these regulations and may be required to incur additional expenses. Management is not able to estimate any additional expenditures outside the normal course of operations which will be incurred by the Company in future periods in order to comply with these regulations.

Enterprisewide_Sales_Informati

Enterprise-wide Sales Information	3 Months Ended
Enterprise-wide Sales Information	Oct. 31, 2013
Enterprise-wide Sales Information [Abstract]	'
Enterprise-wide Sales Information	'
	Note 9. Enterprise-wide Sales Information

	Enterprise-wide sales information for the three months ended October 31, 2013 and 2012, respectively, consisted of the following:

			Three Months Ended		Three Months Ended
			31-Oct-13		31-Oct-12
	Net Sales
	Ophthalmic		$	8,498	$	8,662
	OEM ⁽¹⁾			6,848		5,749
	Other ⁽²⁾			184		209
	Total		$	15,530	$	14,620
	Net Sales
	Domestic		$	11,869	$	10,832
	International			3,661		3,788
			$	15,530	$	14,620

		-1	Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius Therapeutics LLC (“Mobius”). In addition, deferred revenues of $322,000 from the 2010 settlement with Alcon, Inc. (the “2010 Alcon settlement”) are included in this category for the three months ended October 31, 2013 and 2012, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact our future liquidity.
		-2	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Oct. 31, 2013
Recent Accounting Pronouncements [Abstract]	'
Recent Accounting Pronouncements	'
	Note 10. Recent Accounting Pronouncements

	In March 2013, the Financial Accounting Standards Board ("FASB") issued an accounting standard update requiring an entity to release into net income the entire amount of a cumulative translation adjustment related to its investment in a foreign entity when as a parent it either sells a part or all of its investment in the foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets within the foreign entity. This accounting standard update will be effective for the Company beginning in the first quarter of fiscal 2015. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

	In July 2013, the FASB issued an accounting standard update that provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward or a tax credit carryforward exists. Under the new standard update, unrecognized tax benefit, or a portion of an unrecognized tax benefit, is to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward or a tax credit carryforward. This accounting standard update will be effective for the Company beginning in the first quarter fiscal 2015 and applied prospectively with early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

	The Company has reviewed all other recently issued, but not yet effective, accounting pronouncements and does not believe any such pronouncements will have a material impact on its financial statements.

OEM_Partner_Agreements_Tables

OEM Partner Agreements (Tables)	3 Months Ended
	Oct. 31, 2013
OEM Partner Agreements [Abstract]	'
Total sales to marketing partners and their respective percent of the Company's net sales	'
	Codman

	In the neurosurgical market, the bipolar electrosurgical system manufactured by Valley Forge prior to the merger has been sold for over 30 years through a series of distribution agreements with Codman, an affiliate of Johnson & Johnson. On April 2, 2009, the Company executed a three-year distribution agreement with Codman for the continued distribution by Codman of certain bipolar generators and related disposables and accessories, effective January 1, 2009. In addition, the Company entered into a new, three-year license agreement, which provides for the continued licensing of the Company’s Malis^® trademark to Codman for use with certain Codman products, including those covered by the distribution agreement.

	On November 16, 2009, the Company announced the signing of an addendum to its agreement with Codman. Under the terms of the revised agreement, Codman has the exclusive right to market and distribute the Company’s Malis^® branded disposable bipolar forceps produced by Synergetics. Codman began distribution of the disposable bipolar forceps on December 1, 2009, domestically, and on February 1, 2010, internationally.

	Both agreements expired on December 31, 2011 and have renewed for three years. In December 2010, Codman elected to exercise its option of exclusive distribution with respect to the bipolar generators and related disposables and accessories.

	Total sales to Codman and its respective percent of the Company’s net sales in the three months ended October 31, 2013 and 2012, including the historical sales of generators, accessories and disposable cord tubing that the Company has supplied in the past, as well as the disposable bipolar forceps sales resulting from the addendum to the existing distribution agreement, were as follows:

		Three Months Ended			Three Months Ended
		31-Oct-13			31-Oct-12
	Net Sales	$	4,101		$	2,816
	Percent of net sales		26.4	%		19.3	%

	Stryker Corporation (“Stryker”)

	The Company supplies a multi-channel ablation generator, used for minimally invasive pain treatment, to Stryker pursuant to a supply and distribution agreement dated as of October 25, 2004, as amended. The agreement expires on June 30, 2015.

	On March 31, 2010, the Company entered into a supply agreement with Stryker pursuant to which the Company agreed to supply Stryker with disposable ultrasonic aspirator instrument tips and certain other consumable products used in conjunction with Stryker’s ultrasonic aspirator console and handpieces. The agreement expires on March 31, 2016.

	Total sales to Stryker and its respective percent of the Company’s net sales in the three months ended October 31, 2013, and 2012, including the historical sales of pain control generators, and accessories that the Company has supplied in the past, as well as the disposable ultrasonic instrument tips sales and certain other consumable products resulting from the new agreements, were as follows:

		Three Months Ended			Three Months Ended
		31-Oct-13			31-Oct-12
	Net Sales	$	2,162		$	2,559
	Percent of net sales		13.9	%		17.5	%

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Oct. 31, 2013
Stock-Based Compensation [Abstract]	'
Stock options activity	'
	The following table provides information about stock-based awards outstanding at October 31, 2013:

			Shares			Weighted Average		Weighted Average
			Shares			Exercise Price		Fair Value
	Options outstanding beginning of period			747,662		$	4.17	$	3.23
	For the period August 1, 2013 through October 31, 2013
	Granted			--			--		--
	Forfeited			--			--		--
	Exercised			--			--		--
	Options outstanding, end of period			747,662		$	4.17	$	3.23
	Options exercisable, end of period			545,883		$	3.79	$	2.95
Weighted average fair value of options granted and the assumptions used	'
	The fair value of all options granted during the second quarter of fiscal 2013 was determined at the date of the grant using the Black-Scholes option-pricing model and the following assumptions:

	Expected average risk-free interest rate	1.72%
	Expected average life (in years)	10
	Expected volatility	70.50%
	Expected dividend yield	0.00%
Information about restricted stock grants	'
	The following table provides information about restricted stock grants during the three-month period ended October 31, 2013:

			Number of Shares			Weighted Average Grant
			Number of Shares			Date Fair Value
	Balance as of July 31, 2013			405,248		$	3.79
	Granted			--			--
	Forfeited			(2,001	)	$	3.47
	Vested			(51,117	)	$	2.97
	Balance as of October 31, 2013			352,130		$	3.91

Supplemental_Balance_Sheet_Inf1

Supplemental Balance Sheet Information (Tables)	3 Months Ended
Supplemental Balance Sheet Information (Tables)	Oct. 31, 2013
Supplemental Balance Sheet Information [Abstract]	'
Inventories	'
	Inventories: Inventories as of October 31, 2013 and July 31, 2013, respectively, were as follows (dollars in thousands):

		October 31,2013		31-Jul-13
	Raw material and component parts	$	6,786	$	7,418
	Work in progress		1,829		1,133
	Finished goods		7,414		6,274
		$	16,029	$	14,825
Property and equipment	'
	Property and Equipment: Property and equipment as of October 31, 2013 and July 31, 2013, respectively, were as follows:

		31-Oct-13		31-Jul-13
	Land	$	730	$	730
	Building and improvements		6,515		6,365
	Machinery and equipment		8,799		8,665
	Furniture and fixtures		1,040		1,058
	Software		1,108		1,107
	Construction in progress		275		177
			18,467		18,102
	Less accumulated depreciation		9,469		9,140
		$	8,998	$	8,962
Information regarding other intangible assets	'
	Other Intangible Assets: Information regarding the Company’s other intangible assets as of October 31, 2013 and July 31, 2013, respectively, were as follows:

		Gross Carrying		Accumulated		Net
		Value		Amortization		Net
		31-Oct-13
	Proprietary know-how	$	4,057	$	2,348	$	1,709
	Trademark		5,940		--		5,940
	Licensing agreement		5,834		2,834		3,000
	Customer relationships		557		17		540
	Other intangibles		427		13		414
	Patents		2,350		910		1,440
		$	19,165	$	6,122	$	13,043

		31-Jul-13
	Proprietary know-how	$	4,057	$	2,286	$	1,771
	Trademark		5,938		--		5,938
	Licensing agreement		5,834		2,766		3,068
	Customer relationships		531		--		531
	Other intangibles		407		--		407
	Patents		2,270		859		1,411
		$	19,037	$	5,911	$	13,126
Deferred revenue	'
	Deferred Revenue: Deferred revenue as of October 31, 2013 and July 31, 2013, respectively, consisted of the following:

		31-Oct-13		31-Jul-13
	Deferred revenue – Alcon settlement	$	15,496	$	15,818
	Less: Short-term portion		1,288		1,288
	Long-term portion	$	14,208	$	14,530

Enterprisewide_Sales_Informati1

Enterprise-wide Sales Information (Tables)	3 Months Ended
Enterprise-wide Sales Information (Tables)	Oct. 31, 2013
Enterprise-wide Sales Information [Abstract]	'
Enterprise-wide sales information	'
	Enterprise-wide sales information for the three months ended October 31, 2013 and 2012, respectively, consisted of the following:

			Three Months Ended		Three Months Ended
			31-Oct-13		31-Oct-12
	Net Sales
	Ophthalmic		$	8,498	$	8,662
	OEM ⁽¹⁾			6,848		5,749
	Other ⁽²⁾			184		209
	Total		$	15,530	$	14,620
	Net Sales
	Domestic		$	11,869	$	10,832
	International			3,661		3,788
			$	15,530	$	14,620

		-1	Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius Therapeutics LLC (“Mobius”). In addition, deferred revenues of $322,000 from the 2010 settlement with Alcon, Inc. (the “2010 Alcon settlement”) are included in this category for the three months ended October 31, 2013 and 2012, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact our future liquidity.
		-2	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.

Acquisition_of_MISS_Ophthalmic1

Acquisition of MISS Ophthalmics LTD (Details) (USD $)	3 Months Ended		0 Months Ended	3 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Jul. 08, 2013	Oct. 31, 2013
	Oct. 31, 2013	Oct. 31, 2012	M.I.S.S. Ophthalmics Limited [Member]	M.I.S.S. Ophthalmics Limited [Member]
Business Acquisition [Line Items]	'	'	'	'
Cash consideration	'	'	$2,800,000	'
Contribution to revenue due to wholesale distribution activities	'	'	1,100,000	'
Total revenue	15,530,000	14,620,000	'	3,200,000
Intellectual property	'	'	900,000	'
Goodwill	'	'	$1,500,000	'

OEM_Partner_Agreements_Details

OEM Partner Agreements (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012
	Partner	Oct. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Number of U.S. based national and international marketing partners	2	'
Net Sales	$15,530	$14,620
Reporting threshold (in hundredths)	10.00%	'
Codman collaborative arrangement [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Numbers of years a product was sold	'30 years	'
Net Sales	4,101	2,816
Percent of net sales (in hundredths)	26.40%	19.30%
Codman collaborative arrangement [Member] \| Bipolar generators and related disposables and accessories [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Collaborative arrangement time frame	'3 years	'
Collaborative arrangements extension	'3 years	'
Codman collaborative arrangement [Member] \| Malis Spetzler Trademark [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Collaborative arrangement time frame	'3 years	'
Collaborative arrangements extension	'3 years	'
Stryker collaborative arrangement [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Net Sales	$2,162	$2,559
Percent of net sales (in hundredths)	13.90%	17.50%

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
Stock-Based Compensation (Details) (USD $)	Oct. 31, 2013	Jan. 31, 2013	Oct. 31, 2012
Future compensation cost expected to be recognized [Abstract]	'	'	'
Fiscal 2014	$225,000	'	'
Fiscal 2015	254,000	'	'
Fiscal 2016	226,000	'	'
Fiscal 2017	88,000	'	'
Weighted average fair value of options granted and the assumptions used [Abstract]	'	'	'
Term of U.S. Treasury yield curve used to estimate average risk-free interest rate	'10 years	'	'
Additional information about options outstanding [Abstract]	'	'	'
Aggregate intrinsic value of stock options	393,000	'	2,000,000
Additional information about exercisable options [Abstract]	'	'	'
Aggregate intrinsic value of exercisable stock options	375,000	'	1,200,000
Stock Options [Member]	'	'	'
Options, Shares [Roll Forward]	'	'	'
Options outstanding, beginning of period (in shares)	747,662	'	'
Granted (in shares)	0	'	'
Forfeited (in shares)	0	'	'
Exercised (in shares)	0	'	'
Options outstanding, end of period (in shares)	747,662	'	'
Options exercisable, end of period (in shares)	545,883	'	'
Options, Weighted Average Exercise Price [Roll Forward]	'	'	'
Options outstanding, beginning of period (in dollars per share)	$4.17	'	'
Granted (in dollars per share)	$0	'	'
Forfeited (in dollars per share)	$0	'	'
Exercised (in dollars per share)	$0	'	'
Options outstanding, end of period (in dollars per share)	$4.17	'	'
Options exercisable, end of period (in dollars per share)	$3.79	'	'
Options, Weighted Average Fair Value [Roll Forward]	'	'	'
Options outstanding, beginning of period (in dollars per share)	$3.23	'	'
Granted (in dollars per share)	$0	'	'
Forfeited (in dollars per share)	$0	'	'
Exercised (in dollars per share)	$0	'	'
Options outstanding, end of period (in dollars per share)	$3.23	'	'
Options exercisable, end of period (in dollars per share)	$2.95	'	'
Weighted average fair value of options granted and the assumptions used [Abstract]	'	'	'
Expected average risk-free interest rate (in hundredths)	1.72%	'	'
Expected average life	'10 years	'	'
Expected volatility (in hundredths)	70.50%	'	'
Expected dividend yield (in hundredths)	0.00%	'	'
Stock Options [Member] \| Directors [Member]	'	'	'
Options, Shares [Roll Forward]	'	'	'
Granted (in shares)	'	60,000	'
Options, Weighted Average Fair Value [Roll Forward]	'	'	'
Compensation expense related to current year	43,000	'	68,000
Stock Options [Member] \| Officers [Member]	'	'	'
Options, Shares [Roll Forward]	'	'	'
Granted (in shares)	'	82,227	'
Options, Weighted Average Fair Value [Roll Forward]	'	'	'
Compensation expense related to current year	17,000	'	'
Vesting period	'	'4 years	'
Compensation expense for stock options related to previous year	48,000	'	48,000
Restricted Stock [Member]	'	'	'
Restricted Stock Grants, Number of Shares [Roll Forward]	'	'	'
Restricted stock awards, beginning of period (in shares)	405,248	'	'
Granted (in shares)	0	'	'
Forfeited (in shares)	-2,001	'	'
Vested (in shares)	-51,117	'	'
End of period (in shares)	352,130	'	'
Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'
Restricted stock awards, beginning of period (in dollars per share)	$3.79	'	'
Granted (in dollars per share)	$0	'	'
Forfeited (in dollars per share)	$3.47	'	'
Vested (in dollars per share)	$2.97	'	'
End of period (in dollars per share)	$3.91	'	'
2001 Stock Plan [Member] \| Restricted Stock [Member]	'	'	'
Additional information about exercisable options [Abstract]	'	'	'
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted	$928,000	'	'
Weighted average period for recognition of unrecognized compensation cost	'4 years	'	'
2001 Stock Plan [Member] \| Restricted Stock [Member] \| Minimum [Member]	'	'	'
Options, Weighted Average Fair Value [Roll Forward]	'	'	'
Vesting period	'3 years	'	'
2001 Stock Plan [Member] \| Restricted Stock [Member] \| Maximum [Member]	'	'	'
Options, Weighted Average Fair Value [Roll Forward]	'	'	'
Vesting period	'5 years	'	'
2005 Non-Employee Directors' Plan [Member] \| Stock Options [Member] \| Directors [Member]	'	'	'
Options, Weighted Average Fair Value [Roll Forward]	'	'	'
Options issued (in shares)	10,000	'	'

Supplemental_Balance_Sheet_Inf2

Supplemental Balance Sheet Information (Details) (USD $)

0 Months Ended

3 Months Ended

0 Months Ended

Sep. 21, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 08, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Jul. 31, 2013

Alcon settlement [Member]

Revolving Credit Facility [Member]

Equipment Line of Credit [Member]

M.I.S.S. [Member]

Proprietary Know-How [Member]

Trademark [Member]

Licensing Agreements [Member]

Customer Relationships [Member]

Other Intangibles [Member]

Patents [Member]

Land [Member]

Building and improvements [Member]

Machinery and equipment [Member]

Furniture and fixtures [Member]

Software [Member]

Construction in progress [Member]

Covenant

Inventories [Abstract]

Raw material and component parts

$6,786,000

$7,418,000

Work in progress

1,829,000

1,133,000

Finished goods

7,414,000

6,274,000

Inventory, net

16,029,000

14,825,000

Property, Plant and Equipment [Line Items]

Property and equipment, gross

18,467,000

18,102,000

730,000

6,515,000

6,365,000

8,799,000

8,665,000

1,040,000

1,058,000

1,108,000

1,107,000

275,000

177,000

Less accumulated depreciation

9,469,000

9,140,000

Property and equipment, net

8,998,000

8,962,000

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

19,165,000

19,037,000

4,057,000

5,940,000

5,938,000

5,834,000

557,000

531,000

427,000

407,000

2,350,000

2,270,000

Accumulated Amortization

6,122,000

5,911,000

2,348,000

2,286,000

2,834,000

2,766,000

17,000

13,000

910,000

859,000

Net

13,043,000

13,126,000

1,709,000

1,771,000

5,940,000

5,938,000

3,000,000

3,068,000

540,000

531,000

414,000

407,000

1,440,000

1,411,000

Goodwill acquired

10,660,000

1,568,000

Other intangible assets acquired

984,000

Amortization included in general and administrative expense

180,000

Future amortization expense [Abstract]

2014

800,000

2015

800,000

2016

800,000

2017

800,000

2018

800,000

Line of Credit Facility [Line Items]

Maximum borrowing capacity

9,500,000

1,000,000

Current borrowing capacity

8,900,000

Description of variable rate basis

'The one-, two- or three-month LIBOR plus

'one-month LIBOR

Basis spread on variable rate (in hundredths)

2.00%

3.00%

Interest rate at period end (in hundredths)

2.24%

Interest charge on unused portion of facility (in hundredths)

0.20%

Borrowings under credit facility

Maturity date

30-Sep-16

Number of financial covenants

Maximum leverage ratio

3.75

Minimum fixed charge coverage ratio

1.1

Leverage ratio

0.61

Fixed charge coverage ratio

553.1

Minimum interest rate (in hundredths)

3.50%

Deferred Revenue Arrangement [Line Items]

Deferred revenue

15,496,000

15,818,000

Less: Short-term portion

1,288,000

Long-term portion

$14,208,000

$14,530,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (Change in Control Agreement [Member])	3 Months Ended
	Oct. 31, 2013
Change in Control Agreement [Member]	'
Change in Control [Line Items]	'
Time frame for agreement to expire after the change of control	'1 year
Time frame to enter into a separation agreement after termination	'30 days
Number of years of base salary to be paid per agreement	'1 year
Number of monthly equal installments to be paid after termination	'12 months
Time frame for all awards to be exercised after termination	'1 year

Enterprisewide_Sales_Informati2

Enterprise-wide Sales Information (Details) (USD $)	3 Months Ended
Enterprise-wide Sales Information (Details) (USD $)	Oct. 31, 2013		Oct. 31, 2012
Revenue from External Customer [Line Items]	'		'
Net sales	$15,530,000		$14,620,000
Revenues from External Customers [Line Items]	'		'
Net sales	15,530,000		14,620,000
Alcon [Member]	'		'
Revenues from External Customers [Line Items]	'		'
Recognition of deferred revenue	322,000		322,000
Domestic [Member]	'		'
Revenues from External Customers [Line Items]	'		'
Net sales	11,869,000		10,832,000
International [Member]	'		'
Revenues from External Customers [Line Items]	'		'
Net sales	3,661,000		3,788,000
Ophthalmic [Member]	'		'
Revenue from External Customer [Line Items]	'		'
Net sales	8,498,000		8,662,000
OEM [Member]	'		'
Revenue from External Customer [Line Items]	'		'
Net sales	6,848,000	[1]	5,749,000	[1]
Other [Member]	'		'
Revenue from External Customer [Line Items]	'		'
Net sales	$184,000	[2]	$209,000	[2]

[1]	Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius Therapeutics LLC (bMobiusb). In addition, deferred revenues of $322,000 from Alcon are included in this category for the three months ended October 31, 2013 and 2012, respectively.
[2]	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.